We can’t show the full text here under this license.
Remimazolam versus sevoflurane and the risk of confusion after hip replacement in older patients
Updated
Abstract
A total of 456 older patients will be evaluated for the incidence of (POD) after receiving either remimazolam tosilate or sevoflurane during total hip arthroplasty.
- Postoperative delirium is a common complication associated with adverse outcomes following surgery.
- Advanced age and hip surgery are identified as significant risk factors for developing POD.
- The primary outcome will assess the prevalence of POD during the first 4 postoperative days.
- Secondary outcomes include cognitive function, pain levels, postoperative nausea and vomiting, recovery time, and length of hospital stay.
Simplified
Key numbers
19.7%
Incidence of in sevoflurane group
Estimated incidence of based on previous studies.
9.9%
Incidence of in remimazolam tosilate group
Projected prevalence based on preliminary experiments.
456
Total participants planned
Total number of participants to be enrolled across six centers.